Aurinia Pharmaceuticals Inc (AUPH) Sees Significant Growth in Short Interest
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) was the recipient of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 11,398,745 shares, a growth of 13.7% from the October 13th total of 10,028,331 shares. Based on an average daily volume of 1,861,050 shares, the days-to-cover ratio is currently 6.1 days. Approximately 23.6% of the shares of the company are short sold.
Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada increased its holdings in shares of Aurinia Pharmaceuticals by 8.6% during the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 1,341 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Aurinia Pharmaceuticals by 13,197.5% during the third quarter. Wells Fargo & Company MN now owns 26,595 shares of the biotechnology company’s stock valued at $166,000 after purchasing an additional 26,395 shares during the period. Investment Centers of America Inc. acquired a new position in shares of Aurinia Pharmaceuticals during the second quarter valued at $184,000. Cutler Capital Management LLC acquired a new position in shares of Aurinia Pharmaceuticals during the second quarter valued at $184,000. Finally, Kazazian Asset Management LLC increased its holdings in shares of Aurinia Pharmaceuticals by 47.3% during the second quarter. Kazazian Asset Management LLC now owns 66,304 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 21,304 shares during the period. 27.74% of the stock is currently owned by institutional investors.
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at $5.77 on Tuesday. Aurinia Pharmaceuticals has a one year low of $2.02 and a one year high of $10.54.
Several equities analysts recently issued reports on the company. Leerink Swann raised their price objective on Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the stock an “outperform” rating in a research note on Monday, October 23rd. BidaskClub cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Canaccord Genuity set a $11.00 target price on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 24th. Vetr cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.72 target price on the stock. in a research note on Monday, August 14th. Finally, Cantor Fitzgerald set a $14.00 target price on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, August 11th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Aurinia Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $10.79.
COPYRIGHT VIOLATION WARNING: “Aurinia Pharmaceuticals Inc (AUPH) Sees Significant Growth in Short Interest” was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/aurinia-pharmaceuticals-inc-auph-sees-significant-growth-in-short-interest/1701253.html.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.